Postmarketing surveillance study of KOGENATE® Bayer with Bio-Set® in patients with haemophilia A: Evaluation of patients' satisfaction after switch to the new reconstitution system

Haemophilia

Volumn 16, Issue 1, 2010, Pages 66-71

  Vidovic, N ^a   Musso, R ^b   Klamroth, R ^c   Enriquez, M M ^d   Achilles, K ^e  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF CATANIA   (Italy)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d BAYER PHARMA AG   (Germany)

^e BAYER AG   (Germany)

Author keywords

Haemophilia A; Kogenate; Patient preference; Reconstitution; RFVIII; RFVIII FS

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; CHILD; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; EUROPE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SAFETY; PATIENT SATISFACTION; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HOME INFUSION THERAPY; HUMANS; INFANT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 73949154857     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02113.x     Document Type: Article

References (14)

1. Guidelines for the Management of Hemophilia 2005, http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdf, Available at: (last accessed on 18 September 2009)
2. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007, 13:16-22.
3. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007, MASAC Document 179, Revised November 2007. Available at: (last accessed on 18 September 2009)
4. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001, 7:392-6.
5. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006, 12:75-81.
6. Khair K. Evaluating a self infusion device for children with haemophilia. Paediatr Nurs 2006, 18:19-20.
7. Children's opinions of transfer devices for reconstitution of factor VIII/IX BC, Canada, Vancouver, May 21-25, 2006
8. Chalupka SM, Markkanen P, Galligan C, Quinn M. Sharps injuries and bloodborne pathogen exposures in home health care. AAOHN J 2008, 56:15-29.
9. Wicker S, Ludwig AM, Gottschalk R, Rabenau HF. Needlestick injuries among health care workers: occupational hazard or avoidable hazard? Wien Klin Wochenschr 2008, 120:486-92.
10. KOGENATE® Bayer. Summary of Product Characteristics 2007, Germany, Leverkusen
11. Butler R, Larson P, Mannix S. Evaluation of user preference for a needleless factor VIII delivery device for haemophilia patients. J Outcomes Res 2004, 8:63-78.
12. Brewster J, Mannix S, Butler R, Lloyd A, Rentz AM, Larson P. Time and cost savings with Bio-Set device in reconstituting FVIII concentrate [abstract]. Blood 2004, 104:5303.
13. Goldmann G, Klamroth R, Haupt V, Kellermann E. Patients' satisfaction with a new reconstitution system for KOGENATE Bayer: initial German experiences [abstract]. Haemophilia 2006, 12:PO965.
14. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.